Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Valeant Said to Shorten 10-Year Notes to Five in Debt Offering

Don't Miss Out —
Follow us on:

June 25 (Bloomberg) -- Valeant Pharmaceuticals International Inc., the drug distributor acquiring Bausch & Lomb Holdings Inc., dropped plans to issue 10-year notes as part of a $3.23 billion bond sale, instead offering five-year securities.

The shorter bonds may yield about 6.75 percent and eight-year debt may pay about 7.5 percent in a sale planned for June 27, according to a person with knowledge of the transaction, who asked not to be identified because terms aren’t set. The drugmaker had marketed the eight-year notes alongside the 10-year securities starting last week.

The company is also planning $4.05 billion in loans to help fund the purchase, according to a person with knowledge of that transaction.

To contact the reporter on this story: Sarika Gangar in New York at sgangar@bloomberg.net

To contact the editor responsible for this story Alan Goldstein at agoldstein5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.